HUTCHMED Initiates Phase II/III Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naïve Pancreatic Ductal Adenocarcinoma in Collaboration with Hengrui marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
HUTCHMED Initiates Phase II/III Trial with Hengrui | Company Announcement investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.
In June, the FDA is expected to decide whether to approve tarlatamab for SCLC and imetelstat for MDS. In June, the FDA is expected to decide whether to approve tarlatamab for SCLC and imetelstat for MDS.
GENFIT : Shareholders Letter 16 - May 2024 marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.